Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Intermittent Oral Dosing of CM082 in Patients With wAMD: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy

NCT03710863 is registered in ClinicalTrials.gov with AnewPharma as lead sponsor.

NCT NCT03710863
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03710863 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Intermittent Oral Dosing of CM082 in Patients With wAMD: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy
Lead sponsor
AnewPharma
Phase
Phase 2
Overall status
Unknown status
Start date
November 22, 2018
Completion date
January 1, 2022
Enrollment
64 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration